The company that makes an opioid, Purdue Pharma, is an empire with multiple owners.
It owns most of the world’s largest drug companies, including Johnson & Johnson and Pfizer.
Purdue Pharma also owns the pharmaceutical manufacturing and distribution infrastructure, and the vast majority of the drug companies.
The company has been able to acquire big companies without a bidding war because of its ability to negotiate with suppliers and suppliers without having to compete for the best drugs.
As a result, Purdue is able to negotiate low prices for its products.
The price of the opioid fentanyl has been declining, and Purdue has been forced to pay a steep price for that.
It has been one of the fastest growing drugs on the market.
But the company is still a relatively small company.
Its revenues have grown steadily, and its profits have remained stagnant.
Purdue is the largest private company in the world, with revenues of $4.3 billion.
It’s the fourth-largest drugmaker in the United States.
It was spun off in 2007 and renamed Purdue Pharma Group.
It now has nearly $5 billion in revenue and $1.3 trillion in cash.
The other two biggest drugmakers in the country are McKesson, which has $2.6 billion in sales, and Eli Lilly, which owns $1 billion.
But Purdue’s dominance has been in the form of patents, which allow the company to control the manufacture and distribution of its drugs.
The drug company has more than 1,700 patents covering more than 100 different drugs, and it’s a major beneficiary of the U.S. patent system.
In 2010, it paid more than $50 million to settle lawsuits by more than 2,000 plaintiffs over the marketing of the painkiller oxycodone, which was sold over the counter.
Oxycodone’s popularity skyrocketed in the years following the Sept. 11, 2001, terrorist attacks, and that was the reason Purdue purchased it.
Purdue acquired OxyContin in the mid-2000s and began marketing it under the brand name OxyContin Express, which is based on the OxyContin brand name.
Purdue sold OxyContin to Walgreens, which became a subsidiary of Purdue in 2007.
It acquired the drug from Walgers in 2008.
The pharmaceutical company is now controlled by its parent company, Purdue Corporation, through its parent companies.
It still owns its drug companies and has a large share of the global market.
Purdue is a relatively large company.
It does not have a public stock offering.
It makes $4 billion in profits every year.
Purdue does have a number of public pension funds, but those funds have no direct stake in the company.
It has about $9 billion in debt, and about $2 billion of it is due to pension funds.
The debt has been paid off over the past 10 years.
It is not due to inflation, so it’s not a huge amount of debt.
Purdue has a long history of debt payments, and those payments have been steady since the late 1990s.
The company is very profitable.
It earns $1 million in annual profits.
The last quarter of 2011 saw a loss of $1,742 million.
That is about 10% of its annual revenue.
Purdue’s revenue has been flat for the past several years, and is expected to be flat this year.
In addition to its patent portfolio, Purdue has several other assets that it can buy for a substantial profit.
For instance, it can purchase companies that are not profitable enough to be worth buying back.
These include hedge funds, private equity firms, pension funds and pension plans.
The government also has an interest in these assets.
Purdue also owns assets that are subject to the debt, such as intellectual property.
This includes a patent portfolio that is owned by the United Kingdom’s Intellectual Property Office, which oversees the patent portfolio.
It also owns stakes in a number other companies, such a cable television provider and a chemical company.
Purdue owns a number more companies that do not make much profit.
Purdue’s debt has grown substantially since 2007.
If Purdue were to default on its debt, it would not be able to pay its creditors.
The federal government could impose a moratorium on payments until 2019, and Congress could impose some limits on payments.
If Purdue defaults on its payments, it could cause the stock to plummet and hurt the economy, which could be harmful for the U .
A Purdue spokeswoman told The Washington Times that Purdue does not comment on private negotiations.
The spokeswoman also said the company does not expect any change in its business strategy because it has so much assets.